Search This Blog

Wednesday, January 15, 2020

FDA Ad Com thumbs down on Intellipharmaceutics’ oxycodone ER

In a 2 -24 vote, two FDA advisory committees voted against approval of Intellipharmaceutics’ (OTC:IPCIF) extended-release oxycodone for the management of moderate-to-severe pain.
Yesterday, the same committees unanimously voted against Nektar Therapeutics’ oxycodegol.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)